力生制药：子公司中央药业头孢克洛缓释片通过仿制药一致性评价

Core Viewpoint - The announcement indicates that Lifesun Pharmaceutical's subsidiary, Central Pharmaceutical, has successfully passed the consistency evaluation for the generic drug Cefaclor sustained-release tablets 0.375g, which is beneficial for enhancing market competitiveness [1] Group 1: Product Information - The Cefaclor sustained-release tablets are indicated for the treatment of various conditions including acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, pharyngitis, tonsillitis, sinusitis, uncomplicated lower urinary tract infections, and skin soft tissue infections [1] Group 2: Market Impact - The company believes that passing the consistency evaluation will improve its market competitiveness; however, the sales performance of the product may be influenced by changes in the market environment, leading to uncertainty [1]